Exploring a new HIV prevention method for breastfeeding women in Botswana
Linking HIV Prevention and post-partum care: Safety, efficacy and feasibility of cabotegravir-LA PrEP in high-risk breastfeeding population in Botswana
This study is looking at a long-lasting injectable HIV prevention medication for breastfeeding women in Botswana to see if it’s safe and helps them stay protected from HIV while making it easier to get the care they need after having a baby.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10676833 on NIH RePORTER |
What this research studies
This research investigates the use of an injectable HIV prevention medication called cabotegravir-LA in high-risk breastfeeding women in Botswana. It aims to address challenges in adhering to traditional oral HIV prevention methods by providing a long-acting injectable alternative. The study will evaluate the safety of this medication during breastfeeding and explore effective ways to deliver HIV prevention services alongside post-partum care. By focusing on women during the immediate post-partum period, the research seeks to improve access to HIV prevention for those who are at increased risk.
Who could benefit from this research
Good fit: Ideal candidates for this research are high-risk breastfeeding women in Botswana who have recently given birth.
Not a fit: Patients who are not breastfeeding or who are not at high risk for HIV may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of HIV among breastfeeding women and their infants.
How similar studies have performed: Previous research has shown promising results with injectable HIV prevention methods, indicating potential for success in this novel application.
Where this research is happening
Boston, United States
- Beth Israel Deaconess Medical Center — Boston, United States (Active)
Researchers
- Principal investigator: Zash, Rebecca Marie — Beth Israel Deaconess Medical Center
- Study coordinator: Zash, Rebecca Marie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.